Home/Filings/4/0001415889-24-028287
4//SEC Filing

ZELDIS JEROME B 4

Accession 0001415889-24-028287

CIK 0001070081other

Filed

Dec 3, 7:00 PM ET

Accepted

Dec 4, 5:20 PM ET

Size

20.4 KB

Accession

0001415889-24-028287

Insider Transaction Report

Form 4
Period: 2024-12-02
Transactions
  • Exercise/Conversion

    Common Stock

    2024-12-02$51.00/sh+12,000$612,00026,500 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-12-0212,0000 total
    Exercise: $51.00Exp: 2025-01-02Common Stock (12,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-12-0212,0000 total
    Exercise: $30.86Exp: 2026-01-03Common Stock (12,000 underlying)
  • Sale

    Common Stock

    2024-12-02$52.42/sh3,187$167,06314,500 total
  • Sale

    Common Stock

    2024-12-02$51.44/sh8,813$453,34117,687 total
  • Sale

    Common Stock

    2024-12-02$52.39/sh3,667$192,11414,500 total
  • Exercise/Conversion

    Common Stock

    2024-12-02$30.86/sh+12,000$370,32026,500 total
  • Sale

    Common Stock

    2024-12-02$50.52/sh5,699$287,91320,801 total
  • Sale

    Common Stock

    2024-12-02$51.43/sh2,634$135,46718,167 total
Footnotes (7)
  • [F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024
  • [F2]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.10 to $52.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F3]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.10 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to 50.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F5]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.86 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F6]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.02 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F7]Currently exercisable.

Issuer

PTC THERAPEUTICS, INC.

CIK 0001070081

Entity typeother

Related Parties

1
  • filerCIK 0001433982

Filing Metadata

Form type
4
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 5:20 PM ET
Size
20.4 KB